Literature DB >> 26169259

Cryptococcal Antigen Screening and Preemptive Treatment in a US Cohort of Patients With AIDS.

Yukari C Manabe1, Richard D Moore2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26169259      PMCID： PMC4723667          DOI： 10.1093/cid/civ559

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  9 in total

1.  Serum cryptococcal antigen in patients with AIDS.

Authors:  M Feldmesser; C Harris; S Reichberg; S Khan; A Casadevall
Journal:  Clin Infect Dis       Date:  1996-10       Impact factor: 9.079

2.  Evaluation of a novel point-of-care cryptococcal antigen test on serum, plasma, and urine from patients with HIV-associated cryptococcal meningitis.

Authors:  Joseph N Jarvis; Ann Percival; Sean Bauman; Joy Pelfrey; Graeme Meintjes; G Ntombomzi Williams; Nicky Longley; Thomas S Harrison; Thomas R Kozel
Journal:  Clin Infect Dis       Date:  2011-09-21       Impact factor: 9.079

3.  Cost-effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4+ cell count < or = 100 cells/microL who start HIV therapy in resource-limited settings.

Authors:  David B Meya; Yukari C Manabe; Barbara Castelnuovo; Bethany A Cook; Ali M Elbireer; Andrew Kambugu; Moses R Kamya; Paul R Bohjanen; David R Boulware
Journal:  Clin Infect Dis       Date:  2010-08-15       Impact factor: 9.079

4.  Prevalence, correlates, and outcomes of cryptococcal antigen positivity among patients with AIDS, United States, 1986-2012.

Authors:  Jennie McKenney; Sean Bauman; Brandon Neary; Roger Detels; Audrey French; Joseph Margolick; Brian Doherty; Jeffrey D Klausner
Journal:  Clin Infect Dis       Date:  2014-11-24       Impact factor: 9.079

5.  Implementation and operational research: Integrated pre-antiretroviral therapy screening and treatment for tuberculosis and cryptococcal antigenemia.

Authors:  Lincoln Pac; Mara Murray Horwitz; Anne Marion Namutebi; Brandon J Auerbach; Aggrey Semeere; Teddy Namulema; Miriam Schwarz; Robert Bbosa; Allan Muruta; David B Meya; Yukari C Manabe
Journal:  J Acquir Immune Defic Syndr       Date:  2015-04-15       Impact factor: 3.731

6.  Screening for cryptococcal antigenemia in patients accessing an antiretroviral treatment program in South Africa.

Authors:  Joseph N Jarvis; Stephen D Lawn; Monica Vogt; Nonzwakazi Bangani; Robin Wood; Thomas S Harrison
Journal:  Clin Infect Dis       Date:  2009-04-01       Impact factor: 9.079

7.  Asymptomatic serum cryptococcal antigenemia and early mortality during antiretroviral therapy in rural Uganda.

Authors:  Cheryl A Liechty; Peter Solberg; Willy Were; John Paul Ekwaru; Ray L Ransom; Paul J Weidle; Robert Downing; Alex Coutinho; Jonathan Mermin
Journal:  Trop Med Int Health       Date:  2007-08       Impact factor: 2.622

8.  Epidemiology of cryptococcal meningitis in the US: 1997-2009.

Authors:  Vasilios Pyrgos; Amy E Seitz; Claudia A Steiner; D Rebecca Prevots; Peter R Williamson
Journal:  PLoS One       Date:  2013-02-15       Impact factor: 3.240

9.  Cost effectiveness of cryptococcal antigen screening as a strategy to prevent HIV-associated cryptococcal meningitis in South Africa.

Authors:  Joseph N Jarvis; Thomas S Harrison; Stephen D Lawn; Graeme Meintjes; Robin Wood; Susan Cleary
Journal:  PLoS One       Date:  2013-07-19       Impact factor: 3.240
  9 in total
  2 in total

Review 1.  HIV-Associated Cryptococcal Meningitis: Bridging the Gap Between Developed and Resource-Limited Settings.

Authors:  Mark W Tenforde; Rae Wake; Tshepo Leeme; Joseph N Jarvis
Journal:  Curr Clin Microbiol Rep       Date:  2016-03-17

2.  Extent of Lung Involvement and Serum Cryptococcal Antigen Test in Non-Human Immunodeficiency Virus Adult Patients with Pulmonary Cryptococcosis.

Authors:  Tao Zhu; Wan-Ting Luo; Gui-Hua Chen; Yue-Sheng Tu; Shuo Tang; Huo-Jin Deng; Wei Xu; Wei Zhang; Di Qi; Dao-Xin Wang; Chang-Yi Li; He Li; Yan-Qiao Wu; Shen-Jin Li
Journal:  Chin Med J (Engl)       Date:  2018-09-20       Impact factor: 2.628
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.